- Home
- SNTI vs STKS Comparison
SNTI vs STKS Comparison
Compare SNTI & STKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNTI | STKS |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 56.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SNTI | STKS |
|---|---|---|
| Price | $1.10 | $2.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $9.00 | $4.50 |
| AVG Volume (30 Days) | ★ 4.6M | 39.3K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $820,588,000.00 |
| Revenue This Year | N/A | $25.10 |
| Revenue Next Year | $150.00 | $6.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 51.57 |
| 52 Week Low | $1.04 | $1.70 |
| 52 Week High | $5.10 | $5.26 |
Technical Indicators
Market Signals| Indicator | SNTI | STKS |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 61.98 |
| Support Level | $1.15 | $1.70 |
| Resistance Level | $1.28 | $1.85 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 25.36 | 57.63 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.